肺癌联合治疗方法的重大进展

The optimization of the lung cancer treatment

在2014年,随着理解涉及肺癌患者的抗靶向药物逃离信号通路的进展,导致了应对抗靶向药物治疗路径的改进。厄洛替尼治疗,新的联合用药疗法,药物基因组驱动的个性化铂类药物化疗,以及应用PET评估,这些方法的潜在价值代表了另一项关键的重大进展。

With understanding involving the lung cancer resistance to targeted drugs related to escape the signaling pathways,the progress should be lead to the improvement anti-targeted drugs treatment path in 2014. For lung cancer treatment,new combination therapy and chemotherapy drug based on genome-driven personalized platinum drugs,how to manage the potential value of these drugs usage for PET therapy represents another key progress.